Genmab — Oktober 2016
-
Artikel om POLLUX fra Newsmax med henvisninger til NEJM http://www.newsmax.com/Health/Health-News/drug-trio-melanoma-daratumumab/2016/10/07/id/752162/
-
Lignende artikel fra CancerNetwork http://www.cancernetwork.com/multiple-myeloma/daratumumab-combo-significantly-improved-pfs-relapsed-myeloma
-
Og endnu en artikel fra FiercePharma http://www.fiercepharma.com/marketing/j-j-s-darzalex-posts-standout-data-myeloma-cutting-progression-risk-63
-
Tak GB..
-
FDA i USA tildeler Priority Review-status til daratumumab i kombination med lenalidomid og dexamethason, eller bortezomib og dexamethason til behandling af recidiverende myelomatose — PDUFA-dato sat til 17. februar 2017
FDA i USA tildeler Standard Review-status til daratumumab i kombination med pomalidomid og dexamethason til behandling af recidiverende eller refraktær myelomatose — PDUFA-dato sat til 17. juni 2017 -
Godkendelse op til ASH virker nu meget sandsynligt
-
Nyt studie fra Janssen, phase 2, Dara mono, Lymphoma, Taiwan, 32 patienter. En indikation jeg aldrig har hørt om: https://clinicaltrials.gov/ct2/show/NCT02927925
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind